Unicycive Therapeutics, Inc.
UNCY- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001766140
No open-market purchases or sales by Unicycive Therapeutics, Inc. insiders were filed in the last 90 days; 79 institutions reported holding it in 13F filings for Q2 2026, worth $54.6M in total; no superinvestor holds it.
Q3 2022 vs. Q2 2022
How the institutions holding Unicycive Therapeutics, Inc. changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Of which not filed for Q3 2022 | Q3 2022 | Change |
|---|---|---|---|---|
| Holders | 15 | 1 | 12 | −2 |
| Shares | 1.19M | 18.8K | 968.2K | −207.5K (−17.6%) |
| Value | $992.0K | $16.0K | $571.0K | −$405.0K (−41.5%) |
1 institution that held it in Q2 2022 haven't filed for Q3 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (1)
Institutions that held Unicycive Therapeutics, Inc. at the end of Q3 2022 but not at the end of Q2 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Captrust Financial Advisors | 18,800 | $11.0K | 0.00% |
Sold out (3)
Institutions that held Unicycive Therapeutics, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Citadel Advisors LLC | 15,210 | $13.0K |
| Royal Bank of Canada | 5,000 | $4.00K |
| Spire Wealth Management | 1,000 | $1.00K |
Not filed for Q3 2022 yet (1)
Institutions that held Unicycive Therapeutics, Inc. at the end of Q2 2022 and haven't filed a 13F for Q3 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Frontier Wealth Management LLC | 18,800 | $16.0K |